Results indicate that following BNCT, the survival time in mice, receiving PD-CD133/BSH in combination with BSH, with CD133+ SU2 gliomas was significantly different from that of mice receiving PD-CD133/BSH in combination with BSH with CD133− SU2 gliomas (P < 0.05) and mice receiving BSH with CD133+ SU2 gliomas (P < 0.05). This evidence concerns the gene PROM1 and glioma.